Management of Wellbutrin (Bupropion) Pharmacobezoar
For a bupropion pharmacobezoar, immediate endoscopic removal is the priority intervention, as the bezoar can release massive amounts of drug over time leading to life-threatening seizures and cardiovascular complications.
Immediate Assessment and Stabilization
The primary concern with bupropion pharmacobezoars is the risk of delayed massive drug release causing:
- Generalized seizures (most common serious complication)
- Severe CNS depression
- Cardiac dysrhythmias
- Serotonin syndrome (when combined with other serotonergic agents)
Key clinical features to monitor:
- Onset of seizures typically occurs within 2-21.5 hours post-ingestion 1
- "Jittery"/anxious/agitated symptoms are harbingers of more severe toxicity—83% of patients who developed seizures or serious adverse events exhibited these symptoms 2
- Tachycardia and palpitations occur in approximately 12% of cases 2
Treatment Algorithm
1. Endoscopic Removal (First-Line)
- Perform urgent upper endoscopy to visualize and remove the pharmacobezoar
- Pharmacobezoars can contain 40+ tablets that continue releasing drug 1
- This is the definitive intervention to prevent ongoing absorption and life-threatening toxicity
2. Seizure Prophylaxis and Management
- Benzodiazepines are first-line for seizure control
- Avoid medications that lower seizure threshold
- Note: Bupropion is contraindicated in patients with seizure disorders 3
- Seizure risk increases with doses >900 mg, though seizures have occurred at 600 mg 2
3. Supportive Care
- Continuous cardiac monitoring for dysrhythmias
- Monitor vital signs closely, especially during the first 24 hours
- IV access and fluid resuscitation as needed
- Avoid medications that prolong QT interval or increase serotonin (risk of serotonin syndrome with bupropion's serotonergic activity) 4, 5
4. Extended Observation
- Minimum 24-hour observation even after bezoar removal
- Median seizure onset is 7 hours but can occur up to 21.5 hours post-ingestion 2
- Monitor for delayed toxicity from residual drug absorption
Critical Pitfalls to Avoid
Do not rely on activated charcoal alone for pharmacobezoars—the intact tablet mass prevents adequate charcoal contact and the bezoar will continue releasing drug.
Do not discharge patients with minor symptoms early—"jittery" or anxious symptoms strongly predict progression to seizures and should prompt extended monitoring 2.
Do not use whole bowel irrigation as primary therapy—while it may help with distal tablets, it does not address the gastric bezoar mass that requires mechanical removal.
Prognostic Factors
- Dose-related toxicity: Moderate outcomes occur at mean doses of 1,250 mg vs. 694 mg for minor/no effects 2
- Intracranial blood levels: Fatal cases show bupropion levels around 1.9 mg/L with threobupropion as the most abundant metabolite 1
- Tissue distribution: Highest concentrations accumulate in liver (12.3 mg/kg in fatal cases) 1
Post-Removal Management
After successful bezoar removal:
- Continue cardiac and neurological monitoring for 24 hours minimum
- Check for residual tablets via repeat imaging if clinical deterioration occurs
- Psychiatric evaluation before discharge given intentional overdose risk
- Counsel on proper medication administration to prevent recurrence
The combination of immediate endoscopic removal plus aggressive supportive care with seizure prophylaxis offers the best chance of preventing morbidity and mortality from bupropion pharmacobezoars 1, 2.